RA Capital Management’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

RA Capital Management’s Portfolio DRNA Stock Details DRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-2,456,669	Closed	-$35.3M	–	41
2019 Q3	$35.3M	Hold	2,456,669	–	–	2.1%	15
2019 Q2	$38.7M	Hold	2,456,669	–	–	2.08%	12
2019 Q1	$36M	Hold	2,456,669	–	–	1.55%	19
2018 Q4	$26.3M	Sell	2,456,669 -1,476,820	-38%	-$19.4M	1.53%	19
2018 Q3	$60M	Hold	3,933,489	–	–	3.21%	11
2018 Q2	$48.2M	Hold	3,933,489	–	–	3.13%	13
2018 Q1	$37.6M	Sell	3,933,489 -1,032,024	-21%	-$11.1M	2.88%	8
2017 Q4	$44.8M	Buy	4,965,513 +2,536,942	+104%	+$18.7M	3.75%	8
2017 Q3	$14M	Hold	2,428,571	–	–	1.26%	19
2017 Q2	$7.7M	Hold	2,428,571	–	–	0.88%	19
2017 Q1	$8.26M	Hold	2,428,571	–	–	1.01%	19
2016 Q4	$6.99M	Hold	2,428,571	–	–	0.99%	16
2016 Q3	$14.3M	Hold	2,428,571	–	–	1.47%	16
2016 Q2	$7.29M	Hold	2,428,571	–	–	1.01%	20
2016 Q1	$13M	Hold	2,428,571	–	–	1.66%	19
2015 Q4	$28.8M	Hold	2,428,571	–	–	2.85%	12
2015 Q3	$19.9M	Hold	2,428,571	–	–	2.86%	13
2015 Q2	$33.9M	Hold	2,428,571	–	–	3.41%	9
2015 Q1	$58.4M	Hold	2,428,571	–	–	5.8%	6
2014 Q4	$40M	Hold	2,428,571	–	–	4.3%	8
2014 Q3	$30.9M	Hold	2,428,571	–	–	3.65%	8
2014 Q2	$54.8M	Hold	2,428,571	–	–	5.54%	6
2014 Q1	$68.6M	Buy	+2,428,571	New	+$90.2M	4.92%	6

Other funds holding DRNA

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Bridger Management New York $128M AUM 9.54% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

RA Capital Management's DRNA Position: Q4 2019 in Review

RA Capital Management sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2019, closing a stake of 2,456,669 shares — an estimated $35.3M sold.

RA Capital Management first reported a position in DRNA in Q1 2014 and held it in 23 quarters. The position peaked at $68.6M in Q1 2014. 169 funds tracked by Wall St. Rank hold DRNA as of Q4 2019.

RA Capital Management reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2019 after selling out during the quarter.
RA Capital Management sold 2,456,669 Dicerna Pharmaceuticals, Inc. shares in Q4 2019, an estimated $35.3M.
RA Capital Management first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2014 and held it in 23 quarters.
RA Capital Management's Dicerna Pharmaceuticals, Inc. position peaked at $68.6M in Q1 2014.
169 funds tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2019.

Based on RA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.